Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California
© Ereman et al; licensee BioMed Central Ltd. 2010
Received: 30 September 2009
Accepted: 30 April 2010
Published: 30 April 2010
Recent declines in invasive breast cancer have been reported in the US, with many studies linking these declines to reductions in the use of combination estrogen/progestin hormone therapy (EPHT). We evaluated the changing use of postmenopausal hormone therapy, mammography screening rates, and the decline in breast cancer incidence specifically for Marin County, California, a population with historically elevated breast cancer incidence rates.
The Marin Women's Study (MWS) is a community-based, prospective cohort study launched in 2006 to monitor changes in breast cancer, breast density, and personal and biologic risk factors among women living in Marin County. The MWS enrolled 1,833 women following routine screening mammography between October 2006 and July 2007. Participants completed a self-administered questionnaire that included items regarding historical hormone therapy regimen (estrogen only, progesterone only, EPHT), age of first and last use, total years of use, and reason(s) for stopping, as well as information regarding complementary hormone use. Questionnaire items were analyzed for 1,083 non-Hispanic white participants ages 50 and over. Breast cancer incidence rates were assessed overall and by tumor histology and estrogen receptor (ER) status for the years 1990-2007 using data from the Northern California Surveillance, Epidemiology and End Results (SEER) cancer registry.
Prevalence of EPHT use among non-Hispanic white women ages 50 and over declined sharply from 21.2% in 1998 to 6.7% by 2006-07. Estrogen only use declined from 26.9% in 1998 to 22.4% by 2006-07. Invasive breast cancer incidence rates declined 33.4% between 2001 and 2004, with drops most pronounced for ER+ cancers. These rate reductions corresponded to declines of about 50 cases per year, consistent with population attributable fraction estimates for EPHT-related breast cancer. Self-reported screening mammography rates did not change during this period. Use of alternative or complementary agents did not differ significantly between ever and never hormone users. Of women who reported stopping EPHT in the past 5 years, 60% cited "health risks" or "news reports" as their primary reasons for quitting.
A dramatic reduction in EPHT use was followed temporally by a significant reduction in invasive and ER+ breast cancer rates among women living in Marin County, California.
The incidence of invasive breast cancer among non-Hispanic white women declined in the early part of this decade after a long period of increase [1–7]. Investigators surmised that the decrease could be due to one or more of several factors: decreases in use of combination estrogen-progestin menopausal hormone therapy (EPHT), treatment of in situ cancers, and saturation or decline in mammography screening. Although changes in mammography utilization could account for some of the decrease in incidence at the population level, sharp declines have been noted among populations subjected to uniform mammographic screening, indicating that the decline at the population level is unlikely to be due entirely to a change in mammography and is more likely to be explained by declines in EPHT utilization . Large-scale reductions in utilization of EPHT are thought to have occurred after reports of negative health effects of EPHT from the Heart and Estrogen/Progestin Replacement Study (HERS)  and Women's Health Initiative (WHI) .
Marin County, California has received media and research attention due to high breast cancer rates in the mid- to late- 1990s. Earlier reports indicated that Marin County's incidence rates were 28% higher than other San Francisco Bay Area counties and 38% higher than other urban California counties combined . In a case-control study of breast cancers conducted in 1997-99 in Marin County, Wrensch et al.  found no difference in ever use of EPHT in breast cancer cases compared to controls (35.4% vs. 36%, respectively). After the excess breast cancer incidence in Marin County was shown to be due to a disproportionate increase in estrogen receptor (ER)-positive breast cancers , a subsequent analysis of the same case-control study revealed that the excess of ER-positive breast cancers could, in part, be related to EPHT . A recent assessment of EPHT usage in 2001 in 41 California counties utilizing data from the California Health Interview Survey (CHIS) , showed that Marin County ranked fourth among California counties with respect to EPHT use prevalence (estimated at 20.4% of all non-Hispanic white women aged 40-79), while overall hormone therapy use in Marin women was not higher than average usage in California. In light of the recent attention to changes in breast cancer and EPHT use, this report summarizes recent trends in breast cancer incidence, mammography screening rates, as well as in hormone therapy use and patterns of discontinuation, in Marin County.
Marin Women's Study
We used data from the Marin Women's Study (MWS), an ongoing prospective cohort study of women in Marin County funded by the CDC to examine breast cancer, breast density, and associated personal and biologic risk factors. The MWS was initiated in 2006 and is approved by the Marin General Hospital IRB. Women with Marin County residences are recruited at mammogram visits at each of six mammography centers in Marin County and at two hospitals in San Francisco that have substantial attendance from Marin County residents. Women scheduled to receive a mammogram are mailed, and asked to return, an enrollment packet (invitation letter, informed consent and releases, and scannable questionnaire). The packet is included with pre-registration materials required by the mammography clinic, but participation in the MWS is voluntary. Approximately 31% of the total population of Marin women are currently participating in the study.
An 87-item questionnaire was developed for use in the MWS, and assesses known and suspected breast cancer risk factors, using validated items where possible. The draft questionnaire was finalized in an iterative fashion such that initial items were pretested for acceptance and understanding in groups of 5-10 women, revised based on pretest results, pretested in another set of individuals, and revised again until the pretest results indicated no further revision was necessary.
Study Population for Current Analysis
The current analysis is a retrospective examination of prior hormone use using a study population drawn from the MWS cohort. For this analysis, we included 1,833 women who attended mammography screening at Marin General Hospital, one of the larger participating clinics, between October 2006 and July 2007. Women were excluded if their mammogram was not a routine screening mammogram (n = 68), were younger than age 50 (n = 494), were missing data on age (n = 17), or were not non-Hispanic white race (n = 171) leaving an analysis population of 1,083.
Breast Cancer Risk Factor Data
Menopausal Hormone Therapy
Women were asked to provide detailed information about their historical use of estrogen without progesterone (pills/patches alone, vaginal estrogen, and estrogen shots) and progesterone without estrogen (creams and pills/patches). Respondents were asked "Have you ever used prescription hormone replacement therapy (HRT) for symptoms of menopause or for other reasons?" To ascertain type of estrogen used, additional follow-up questions were asked, and included: "Have you ever used estrogen pills or patch alone (such as Premarin)?" "Have you ever used vaginal estrogen?" "Have you ever used estrogen shots?" "Have you ever used progestin cream?" "Have you ever used progestin pills or patch alone?" For each type of estrogen or progestin only regimen, women were asked the age when treatment was started and stopped and the total number of years the regimen was used.
In addition, women were asked about their current and past use of EPHT regimens. Women were asked "Have you ever used combination estrogen and progestin (such as Prempro, Premphase, or Premarin with Progestin)?" For each regimen, women were asked to indicate the type of estrogen and number of days a month they used estrogen, the type of progestin and the number of days they used progestin, their age when the regimen was started and stopped, the total number of years taken and the reason the regimen was discontinued (when applicable). Women were asked to document their most recent, or current regimen first. Response boxes were also provided for women to provide the same information on two previous regimens, if applicable.
Complementary and Alternative Medicines
Complementary and alternative medicine (CAM) utilization was ascertained for current use and use in the past 5 years. Stock at local pharmacies was reviewed to ascertain which CAMs to include as response options on the survey. Women were specifically queried about their use of combination herbal remedies (eg. Estroven and Estrohealth), black cohosh, chaste tree or berry, Dong Quai, phytoestrogen/plant estrogens, soy or soy supplements, wild yam and other. Women were asked to estimate the total length of time they used these supplements and the main reason for using it. Specific questions include: "During the past 5 years, have you used any of the following natural hormone supplements at least weekly for 3 or more months in a row?" "Please estimate the total length of time you have used these natural hormone supplements." "What was the main reason you used the natural hormone supplements?"
Based on self-reported start and stop date, yearly prevalence was calculated for estrogen therapy, EPHT and CAMS for single years between 1995 and 2006.
Population Mammography and Hysterectomy Data
Mammography screening and hysterectomy rates for Marin County were ascertained from the California Health Interview Survey (CHIS) [16, 17], using the CHIS 2001 and 2005 Adult Public Use Files. CHIS is a random-digit dial telephone survey of households in every county in California. CHIS covers a wide range of topics, including health status, health conditions, health-related behaviors, health insurance coverage, and access to and use of health care services. Respondents were asked: "Have you EVER had a mammogram?", and if yes, asked "How long ago did you have your most recent mammogram?", and "Have you ever had a hysterectomy?"
Cancer Incidence Data
Annual cancer incidence and population data from 1990-2007 for Marin County and California were obtained from the Northern California Cancer Center, a part of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. Analyses included new cases of invasive breast cancer using International Classification of Diseases - Oncology, 2nd edition, site codes 50.0-50.9 excluding histology codes 9590-9989 among non-Hispanic white women aged 50 years or older. For the purposes of this report and consistent with earlier reports documenting a particular increase in lobular cancer for Marin County , all invasive breast cancers were subdivided for stratified analysis into the following hormonal and histologic groups: estrogen receptor positive (ER+), estrogen receptor negative (ER-), lobular cases (ICD-0-3 morphology codes 8520 and 8522) and non-lobular/ductal cases (all other morphology codes, including unknown histology, but primarily consisting of code 8500/ductal histology).
Stata 8 (Stata Corporation) was used for all analyses of MWS data. Prevalence estimates and their 95% confidence intervals were calculated for each HT regimen for the current year (i.e., at the time of the survey in 2006/2007) and for prior years using recalled data. For years prior to the survey year (2006/2007), prevalence was calculated for women who were aged 50+ in that year (i.e., the denominator for each year only included women aged 50+ in that year). Statistical comparisons of the proportion of women using hormone therapy across years were made by comparing the 95% confidence intervals. A chi-squared statistic and the associated p-value were used to compare the reasons for quitting hormone therapy for those who quit within the past 5 years compared to those who quit 10 or more years ago. The online tool "AskCHIS" was used to calculate the prevalence of mammography use in 2001 and 2005 with 95% confidence intervals, as well as the prevalence of hysterectomy in 2005. SEER*Stat software (version 6.4.4) was used to calculate all age-adjusted and age-specific cancer incidence rates (age-adjusted to the 2000 US population standard), associated standard errors and 95% confidence intervals. Age-adjusted incidence rates were compared statistically using a Wald chi-square test of the difference between two rates with p-values of less than 0.05 considered significantly different. Use of Joinpoint regression was explored in preliminary analyses but yearly case counts were insufficient to detect year to year differences.
Demographic characteristics, non-Hispanic white women ages 50 and over, Marin Women's Study 2006-2007 (n = 1083) and Marin County as a whole.
H.S or less
Postmenopausal Hormone Therapy Use
Hormone therapy usage, non-Hispanic white women ages 50 and over, Marin Women's Study 2006/2007 (n = 1083)
Ever Use -- prescription hormone therapy
Ever Use -- prescription hormone therapy by age category
Current Use -- prescription hormone therapy
EPHT Use by Age and Year
2001 (%, 95% CI)
2006 (%, 95% CI)
21.9 (18.2, 25.7)
10.6 (7.8, 13.2)
21.2 (15.8, 26.6)
9.7 (6.6, 12.8)
5.6 (1.2, 10.0)
4.8 (1.3, 8.4)
The proportion of women currently taking prescription hormone therapy in 2006/2007 in this study population was 26.0%, with 6.7% of women reporting current EPHT use, 22.4% reporting EHT only, and 1.9% progestin only.
We examined the relative decreases in EPHT use taking into consideration the publication of the HERS study in 1998 and the WHI trial in 2002. From 1995 to 1998, EPHT use was steady (0% overall change). Between publication of the HERS and WHI trials (i.e., 1998 to 2001), there was a 14% decrease in EPHT use. The largest decrease occurred after publication of the WHI trial data in 2002. From 2002 to the time of the survey (2006/2007), there was a 57.3% drop in EPHT use.
To understand whether overall changes in EPHT use stemmed from decreases in use for particular age groups, prevalence of use by age group was calculated for the years 2001 and 2006 (Table 2). While use in 2006 was lower than that in 2001 in women 50-59 and 60-69, there was no evidence of changes in use among women aged 70 years and older.
Initiation and Cessation Behavior
Initiation and cessation of prescription hormone therapy by regimen, non-Hispanic white women ages 50 and over in Marin County, 2006-2007
Estrogen Only (EHT)
Past Users who quit within past 5 years
43.8 of past users
Ever Users who started in past 5 years
Current users, time started:
≤5 years ago
> 5-10 years ago
> 10 years ago
Estrogen plus progestin (EPHT)
Past Users who Quit within past 5 years
51.6 of past users
Ever Users who started in past 5 years
Current users, time started:
≤5 years ago
> 5-10 years ago
> 10 years ago
Reasons quit (past users)
Quit < 5 yrs ago
Quit >10 yrs ago
X 2 , p-value
Health or News Reports
The reasons prior users reported stopping EPHT are also shown in Table 3. (These data were not gathered for EHT use.) The proportion of women who cite quitting EPHT due to health effects and/or news reports is significantly greater among those who quit within the past 5 years than among those who quit 10 or more years ago (60.0% vs. 29.6%, respectively). The proportion of those who quit because of a doctor's recommendation was non-significantly higher among those who quit within the past 5 years compared to those who quit 10 or more years ago (32.0% vs. 25.9%), while the proportion citing side effects is significantly lower (11.0% vs. 33.3%, respectively).
Complementary & Alternative Medicines
Prevalence of complementary and alternative medicine (CAM) usage for menopausal symptoms, non-Hispanic white women ages 50 and over, Marin County, 2006-2007 (n = 1083)
Current Users, length of time
1 - 2 years
3 - 4 years
CAM use in women who have ever used hormone therapy
CAM use in women who have never used hormone therapy
Invasive Breast Cancer Incidence Rates
Case counts and age adjusted incidence rates: invasive breast cancer, ER+, ER-, ductal and lobular component, non-Hispanic white women 50+ Marin County, 1990-2007
Invasive Breast Cancer
(374.8 - 526.2)
(215.2 - 334.3)
(29.1 - 84.4)
(294.7 - 427.2)
(191.3 - 300.8)
(28.0 - 81.1)
(348.6 - 491.7)
(248.8 - 371.8)
(37.7 - 96.5)
(415.0 - 567.1)
(277.6 - 404.6)
(44.2 - 105.2)
(363.3 - 504.6)
(253.9 - 374.5)
(31.2 - 83.8)
(387.9 - 533.0)
(279.8 - 405.6)
(29.0 - 80.0)
(445.2 - 598.5)
(340.5 - 476.2)
(36.9 - 91.6)
(445.1 - 595.2)
(341.1 - 474.8)
(39.1 - 93.3)
(424.3 - 569.3)
(323.7 - 452.7)
(34.1 - 84.8)
(452.9 - 599.2)
(336.1 - 464.2)
(47.6 - 103.5)
(401.1 - 538.9)
(279.8 - 398.4)
(49.0 - 105.3)
(449.5 - 594.5)
(349.8 - 479.9)
(37.1 - 87.7)
(418.9 - 558.3)
(336.2 - 462.5)
(22.5 - 65.6)
(309.1 - 428.8)
(231.5 - 336.6)
(40.4 - 92.7)
(291.8 - 406.3)
(131.5 - 212.3)
(38.0 - 87.9)
(353.1 - 478.3)
(151.0 - 235.8)
(26.5 - 71.4)
(353.1 - 476.0)
(157.4 - 242.6)
(23.8 - 64.2)
(392.1 - 522.7)
(172.5 - 262.6)
(35.2 - 83.4)
(261.3 - 390.4)
(52.7 - 120.0)
(234.6 - 354.5)
(12.9 - 54.7)
(216.7 - 333.3)
(29.2 - 81.5)
(234.0 - 352.2)
(63.9 - 132.8)
(212.7 - 324.5)
(67.9 - 137.7)
(238.4 - 355.7)
(84.3 - 159.9)
(269.7 - 392.2)
(67.1 - 136.1)
(303.2 - 429.6)
(61.0 - 126.3)
(282.3 - 403.2)
(68.8 - 135.5)
(258.7 - 372.5)
(104.1 - 182.2)
(282.4 - 400.1)
(41.4 - 96.0)
(235.5 - 344.0)
(114.0 - 194.2)
(232.6 - 340.1)
(83.3 - 152.8)
(169.7 - 262.0)
(64.6 - 125.4)
(189.3 - 284.7)
(55.3 - 111.5)
(229.0 - 332.3)
(49.4 - 103.4)
(207.5 - 303.7)
(66.2 - 127.5)
(254.1 - 361.2)
(74.9 - 140.3)
Breast Cancer Histology and ER Status
The incidence of ER+ tumors in Marin remained relatively constant from 1990 though 2001; ER+ tumors then dropped sharply and significantly between 2002 and 2004, from 395.3/100,000 to 167.9/100,000 representing a reduction of over 57% (34.8% a year) or 88 incident cases (Figure 3). Despite small numbers of cases, there was no evidence of a significant change in ER- tumor incidence during that same time period. Case counts, age-adjusted incidence rates and corresponding confidence intervals are presented in Table 5.
Figure 2 also shows the incidence trends for invasive breast cancers according to histologic subtype. Between 1990 and 2007, 70-80% of all breast cancer cases in Marin County were of ductal/non-lobular histology. Ductal invasive carcinomas decreased significantly in Marin County from 362.2/100,000 (CI 303.2-429.6) in 1997 to a low of 211.8/100,000 (CI 169.7-262.0) in 2003, representing an 8.6% average annual reduction. Despite small numbers of cases for analysis, the pattern in lobular breast cancer incidence differed somewhat from that of ductal breast cancers. Rates of lobular cancers increased throughout the 1990s, with the rates in 1999 and 2001 significantly higher than 1991 and 1992. From 2001-2006, rates decreased somewhat, but these differences did not reach statistical significance.
Prevalence of Mammography Screening
CHIS survey data suggested consistent trends in self-reported rates of biannual mammography screening in Marin County with prevalences of 87.2% (CI 81.7-92.7) in 2001 and 85% (CI 82.8-87.3) in 2005 [16, 17]. In California, the prevalences were 82.7% (81.8-83.7) in 2001 and 83.9% (83.0-84.9) in 2005, not significantly different than the reported screening prevalence in Marin. Differentiation between first and subsequent mammograms could not be ascertained from this data source.
Discussion and Conclusions
Invasive breast cancer incidence rates in Marin County among non-Hispanic white women aged 50 years or older decreased significantly between 2001 and 2004, a reduction of 33% (7.9% per year). The change in incidence rates was evident primarily in women ages 50-79. During the same time period, EPHT utilization dropped more than 50% (9.9% per year) in women 50 and older, and continued to drop through 2006, while mammography screening rates remained stable. The reduction in EPHT utilization preceded the drop in invasive breast cancer incidence rates, and was seen as early as 1998, with a more precipitous drop evident between 2001 and 2004.
Early in the investigation of high breast cancer rates in Marin County, we explored HT use as a possible reason for the high rates. In the absence of more specific data on prevalence of EPHT vs. EHT use, we found that overall HT use in Marin County women ages 50 and over was not significantly different than the prevalence for the entire state of California (CHIS 2001). Subsequent analyses using updated data that differentiated between HT formulations showed that Marin had the 4th highest estimated EPHT prevalence among California counties . One explanation for the high prevalence of EPHT utilization in the absence of excess overall HT use is a difference in the prevalence of hysterectomy. Indeed, further investigation for this manuscript revealed substantial county by county variations in hysterectomy rates throughout California, ranging from 14.9% to 55.8% (San Francisco and Sutter Counties, respectively) in white women ages 50+, with Marin having the second lowest percentage of hysterectomies (23.1%) . Understanding why hysterectomies vary so widely geographically, while not the subject of this manuscript, warrants further investigation.
While our survey did not specifically query women about HERS and WHI and the resulting press coverage, we believe that the reduction in HT use is largely attributable to the publication and subsequent dissemination of these results, as has been documented in other populations. Interestingly, the proportions of women reporting physician-initiated cessation of EPHT did not increase in the post-WHI period (Table 3). This may relate to the high educational status and good media access of the study population in question, which may lead women to discontinue treatment on their own following negative press on EPHT.
Complementary and alternative hormone (CAM) utilization did not significantly increase despite the fact that EPHT and EHT use dropped precipitously, suggesting that women are not replacing prescription hormone therapies with CAMs as a treatment for menopausal symptoms. Future research should address whether women are seeking other therapies to replace EPHT for the treatment of menopausal symptoms, and should address the relative safety and efficacy of these therapies.
Previous assessments in Marin County women suggested that the excess breast cancer incidence relative to other urban California geographic areas was predominantly ER+ lobular and ductal breast cancer cases . Total ER+ Marin breast cancer cases diagnosed between 1997-1998 were associated with excess postmenopausal hormone therapy use . Larger population studies of breast cancer subtypes associated with current and long duration EPHT use have been somewhat contradictory , but in general suggest a link between EPHT use and increased ER+ breast cancer incidence [5, 13, 18]. In the present study, the changing incidence of lobular and ductal breast cancer were not concordant with one another between 1999 and 2003, and changes in total invasive breast cancer incidence over this period largely reflected that of the more commonly diagnosed ductal subtype of breast cancer. Almost all lobular breast cancers and over 60% of ductal breast cancers are ER+; therefore, it is noteworthy that the change in total ER+ breast cancer incidence rates between 1999 and 2003 not only paralleled the change in total invasive breast cancer incidence but showed a precipitous decline after 2001 that better reflects the change in EPHT use than did the decline in ductal breast cancer rates. Following the decline in EPHT use between 2000-2004, ER+ breast cancer incidence rates dropped by >50% while ductal breast cancer incidence dropped by only 29% and lobular rates showed no significant change, but the number of lobular cancers is small making changes in these rates difficult to detect (Figure 2).
To understand whether the observed reduction in EPHT therapy was commensurate with the drop in breast cancer cases seen in Marin County, we referred to a recent analysis of the population-level impact of HT on breast cancer rates which used the population attributable fraction (PAF) to estimate the proportion of breast cancer incidence rates attributable to EPHT . PAF estimates were calculated based on a range of EPHT use (5-22%) and relative risk estimates from the literature (1.24-3.06) for the risk of EPHT on breast cancer. When PAF estimates are calculated in the MWS study population, using an average prevalence of EPHT use (20%) from 1999-2001 and moderate relative risk estimates of 1.5 - 2.0, these PAF estimates would suggest that approximately 22 - 40 cases annually (10-18% of 217 invasive breast cancer cases per year in 2001-2002 in Marin) could be attributable to EPHT use in the years before 2002, commensurate with our observations of 50 fewer cases per year in Marin County.
The drop in invasive breast cancer incidence in 2002-2004 was followed by a non-significant increase in incidence rates in 2005-2007. Determining whether this is a real increase in incidence will only be possible with additional years' data. The increase may be a statistical aberration given the relatively small number of annual cases in Marin (and therefore unstable rates), or could be due to inaccuracies in the population estimates . On the other hand, if the rate increase proves to be real, it could be due to replacement of EPHT by another compound also associated with breast cancer, a rebound emergence of cases after some delay due to promoting influences that only temporarily retarded the emergence of new tumor cases, improved sensitivity of mammography after removal of EPHT which impeded detection of breast cancer , or a reflection of downward resetting of the Marin incidence curve that reveals another underlying increasing incidence trend that has been happening independent of EPHT. It will be important to continue monitoring breast cancer incidence rates, the prevalence of HT and other risk factors, as well as mammography screening changes to determine whether this trend continues.
Mammography screening rates in Marin County, as assessed by a statewide population-based survey [16, 17], decreased non-significantly during the study period, suggesting that a large drop-off in mammography utilization does not explain the breast cancer rate decline in this population. Similarly, in California, reported screening rates did not change significantly during this time period and were not significantly different from those in Marin. Although overall screening rates did not change significantly, a screening saturation effect should also be considered in assessing changes in incidence rates. Specifically, the proportion of mammography-detected cancers that are interval cancers versus existing previously-undiagnosed cancers will vary depending on the extent of screening saturation in the population. A change in the distribution of first to subsequent mammograms (whether cases were detected at first screen, subsequent screen or not screen detected) and thus a change in screen-detected cases, has been shown to explain recent incidence trends outside the U.S. [22, 23], but could not be determined in this study. While screening saturation prior to 2001 cannot be directly assessed in the Marin population using these data, one study reporting on screening patterns in the Western United States , indicates that saturation occurred in the late 1980s to early 1990s. It is not likely that Marin deviated substantially from this pattern. In addition, a recently published manuscript of a California cohort of women with similar demographics to Marin found invasive incidence rates declined significantly in 2003-2005 with consistent levels of screening throughout the study period . Given the high prevalence of EPHT utilization and the substantial, subsequent decline in use in this population, changes in screen-detected cases would need to be considerable during this time period to explain such a dramatic drop in breast cancer rates in Marin, although the possibility cannot be discounted. Future research must continue to monitor mammography utilization patterns alongside EPHT utilization to examine any association with future changes in breast cancer incidence rates.
While this interim analysis of the MWS has a number of strengths, including a large sample size and in-depth individual-level data on use of EPHT and EHT, as well as the reasons for stopping EPHT, there are a number of limitations to this study. The primary limitation is the possibility of selection bias. We were only able to obtain information from women currently living in Marin County, thus excluding women who lived in Marin County during the retrospective study period but who are not available for interview due to out-migration or death. It has been hypothesized that migration of low or high risk women on the basis of changes in the cost of living during the 1990's could have affected geographic patterns in breast cancer incidence [11, 25]. Given the association between EPHT utilization and adverse outcomes, it is possible that our estimates of EPHT use are lower than the true prevalences, as current users may have been more likely to die and thus not be a part of the current study. In addition, the potential for selection bias is also present in the form of preferential participation by women who perceive themselves to be at increased risk of breast cancer. However, our estimates of the prevalences of HT utilization in this study are similar to those published previously , indicating a lack of a strong selection bias.
HT utilization was assessed in this study in a population with uniform access and utilization of mammographic screening, suggesting a potential source of selection bias. As expected, given that this is service-based population, women with lower SES who have less access to care are not well represented the MWS study population. With the exception of the lowest income and education groups, women in the mammography screening population are seen as being representative of the broader population of Marin County women ages 50 and over, as 70% of women in this age group in Marin report having a mammogram in the past year  and approximately 90% report having had a mammogram in the past two years . In addition, the clinic at Marin General Hospital serves clients with both HMO and PPO insurance plans and has referrals from local community clinics for the uninsured to receive low- and no-cost mammography visits. Efforts continue to include low SES women in ongoing MWS recruitment. Though the income distribution may seem to indicate that only high income women are included in the study population, the cost of living in Marin County is very high, thus, these incomes represent the range of incomes found in this area.
A second limitation in the current study is the potential for information bias in the ascertainment of HT utilization. HT utilization was based on self-report, rather than clinical records, and is therefore subject to problems in recall. Again, we do not see this as a major problem in the current study as the estimated prevalence of HT use in 2001 in this study population was similar to that found in two cross-sectional health surveys [16, 17] conducted in Marin County in 2001. In addition, a recent study by Banks et al. , compared medical practice prescription records to self-reported questionnaire data from women participating in the Million Women Study and found excellent agreement between the two.
Another potential source of information bias is in the calculation of breast cancer incidence rates. Cancer incidence trends can be biased by inaccurate cancer registry or population projections if the projections or registry errors change over time. The California Cancer Registry has produced extremely accurate case counts; case ascertainment was estimated at 99% for 2004 . Intercensal population projections, on the other hand, can be substantively incorrect, and have biased breast cancer incidence rate estimation in Marin County in the past decade . We will not be able to ascertain the extent to which bias may be present in the incidence rates until the 2010 Census is conducted.
This study was not able to include a range of potentially confounding risk factors known to play a role in breast cancer incidence rates, as comprehensive risk factor information in the study population were not available at the time of publication. We presented this ecologic, retrospective analysis of breast cancer incidence in relation to hormone therapy use, similar to other published reports [4, 6, 8, 15] which assessed changes in EPHT use after publication of the WHI results. Additional risk factors and their relationship to breast cancer incidence will be the subject of future reports, although current nationwide trends in BMI (increasing), parity (decreasing), and late childbearing (increasing) should tend to increase breast cancer rates if those trends are mirrored in Marin County. We believe it is unlikely that family history of breast cancer changed significantly during this time period to impact breast cancer rates.
Although Marin County is a unique population in terms of education and income, Marin has been a bellwether for cancer trends in the past. In the late 1970's Marin's uterine cancer rates spiked precipitously, providing strong evidence for the potential risks of EHT on the uterus. Thus, despite its distinctive demographics, the relationship between etiologic factors and cancer are not unique to Marin, and are applicable to women across the world. Studying populations with extreme risk factor prevalences can help to signal risk that may be more difficult to study in populations with more moderate prevalence. While the proportion of women using EPHT may not have dipped as low in other populations as it has in Marin County, it has decreased as have breast cancer rates, so the trends and underlying relationship are not unique to Marin County.
In this study we were able to examine breast cancer incidence and the pattern of HT utilization and cessation during a period of dramatically altered views on the health benefits of HT. The extent to which women quit using EPHT and the lower adoption of EPHT in the years following the publication of the HERS and WHI study results is consistent with other reports from elsewhere in California and the US, as was the subsequent decline in breast cancer incidence, particularly ER+ breast cancers, and the estimated proportions of Marin County breast cancers attributable to current EPHT use. Future studies addressing the predictors of HT utilization in the post-WHI era will enhance these results by determining which populations are most affected by this changing behavior, and will therefore be most likely to experience changes in breast cancer incidence. Continued attention to population-based patterns of HT utilization and breast cancer incidence will reveal whether the HERS and WHI trials resulted in a sustained, long-term reduction in the incidence of HT-related breast cancers.
Estrogen plus Progestin Menopausal Hormone Therapy
Marin Women's Study
California Health Interview Survey
Centers for Disease Control
Internal Review Board
Hormone Replacement Therapy
Complementary and Alternative Medicine
National Cancer Institute's Surveillance, Epidemiology, and End Results
Estrogen Hormone Therapy
Heart and Estrogen/progestin Replacement Study
Women's Health Initiative
Population Attributable Fraction
• Dr. Larry Meredith and Frima Stewart from the County of Marin Department of Health and Human Services for their support in conducting this research.
• The administrators and staff at Marin General Hospital, Kaiser Permanente Medical Group and Novato Community Hospital for their generous in-kind assistance for this study - without the support of our medical providers, this research would not be possible.
• The SFMR (San Francisco Mammography Registry) for providing data for the manuscript.
• The Avon Foundation for their ongoing support of the MWS.
• The study participants for their generous participation in the study.
• This work was also supported in part by the Centers for Disease Control, Grant/Cooperative Agreement Number R01 DP000217.
• Congresswoman Lynn Woolsey and Senator Barbara Boxer for their ongoing dedication and support of breast cancer research and prevention services.
Dr. Janet Dahling for her guidance and support in the design and implementation of the MWS.
The collection of cancer incidence data used in this study was supportedby the California Department of Health Services as part of the statewidecancer reporting program mandated by California Health and Safety CodeSection 103885; the National Cancer Institute's Surveillance,Epidemiology and End Results Program under contract N01-PC-35136 awardedto the Northern California Cancer Center, contract N01-PC-35139 awardedto the University of Southern California, and contract N02-PC-15105awarded to the Public Health Institute; and the Centers for DiseaseControl and Prevention's National Program of Cancer Registries, underagreement #U55/CCR921930-02 awarded to the Public Health Institute. Theideas and opinions expressed herein are those of the authors andendorsement by the State of California, Department of Health Services,the National Cancer Institute, and the Centers for Disease Control andPrevention or their contractors and subcontractors is not intended norshould be inferred.
- Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, Jemal A, Miller B, Williams M, Ward E, Wingo PA, et al: Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006, 107 (8): 1711-1742. 10.1002/cncr.22193.View ArticlePubMedGoogle Scholar
- Espey DK, Wu XC, Swan J, Wiggins C, Jim MA, Ward E, Wingo PA, Howe HL, Ries LA, Miller BA, et al: Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007, 110 (10): 2119-2152. 10.1002/cncr.23044.View ArticlePubMedGoogle Scholar
- Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL: Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol. 2003, 102 (6): 1225-1232. 10.1016/j.obstetgynecol.2003.08.007.PubMedGoogle Scholar
- Haas JSKC, Gerstenberger EP, Kerlikowske K: Changes in the Use of Postmenopausal Hormone Therapy After the Publication of Clinical Trail Results. Annals Internal Medicine. 2004, 140: 187-188.View ArticleGoogle Scholar
- Glass AG, Lacey JV, Carreon JD, Hoover RN: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007, 99 (15): 1152-1161. 10.1093/jnci/djm059.View ArticlePubMedGoogle Scholar
- Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007, 356 (16): 1670-1674. 10.1056/NEJMsr070105.View ArticlePubMedGoogle Scholar
- Clarke CKT, Le G, Glaser S, West D: Update on Breast Cancer Incidence Patterns in Marin County and the San Francisco Bay Area, California. BMC Cancer. 2004, 170-Google Scholar
- Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007, 99 (17): 1335-1339. 10.1093/jnci/djm111.View ArticlePubMedGoogle Scholar
- Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB: Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials. 1998, 19 (4): 314-335. 10.1016/S0197-2456(98)00010-5.View ArticlePubMedGoogle Scholar
- Russeau: Women's Health Initiative (WHI). 2002Google Scholar
- Clarke CA, Glaser SL, West DW, Ereman RR, Erdmann CA, Barlow JM, Wrensch MR: Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990-1999. Breast Cancer Res. 2002, 4 (6): R13-10.1186/bcr458.View ArticlePubMedPubMed CentralGoogle Scholar
- Wrensch M, Chew T, Farren G, Barlow J, Belli F, Clarke C, Erdmann CA, Lee M, Moghadassi M, Peskin-Mentzer R, et al: Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Res. 2003, 5 (4): R88-102. 10.1186/bcr605.View ArticlePubMedPubMed CentralGoogle Scholar
- Benz CC, Clarke CA, Moore DH: Geographic excess of estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev. 2003, 12 (12): 1523-1527.PubMedGoogle Scholar
- Hwang ES, Chew T, Shiboski S, Farren G, Benz CC, Wrensch M: Risk factors for estrogen receptor-positive breast cancer. Arch Surg. 2005, 140 (1): 58-62. 10.1001/archsurg.140.1.58.View ArticlePubMedGoogle Scholar
- Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ: Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006, 24 (33): e49-50. 10.1200/JCO.2006.08.6504.View ArticlePubMedGoogle Scholar
- California Health Interview Survey CHIS 2001 Adult Public Use File. UCLA Center for Health Policy Research. 2004, Release 3, Los Angeles CA,
- California Health Interview Survey CHIS 2005 Adult Public Use File. UCLA Center for Health Policy Research. 2007, Release 1, Los Angeles CA,
- Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, et al: Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol. 2003, 21 (23): 4314-4321. 10.1200/JCO.2003.05.151.View ArticlePubMedGoogle Scholar
- Clarke CA, Glaser SL: Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control. 2007, 18 (8): 847-852. 10.1007/s10552-007-9029-1.View ArticlePubMedGoogle Scholar
- Phipps AI, Clarke CA, Ereman RR: Impact of intercensal population projections and error of closure on breast cancer surveillance: examples from 10 California counties. Breast Cancer Res. 2005, 7 (5): R655-660. 10.1186/bcr1266.View ArticlePubMedPubMed CentralGoogle Scholar
- Chlebowski R: Arch Intern Med. 2008, 168: 370-377. 10.1001/archinternmed.2007.123.View ArticlePubMedGoogle Scholar
- Ponti A, Rosso S, Zanetti R, Ricceri F, Tomatis M, Segnan N: Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007, 99 (23): 1817-1818. 10.1093/jnci/djm225.View ArticlePubMedGoogle Scholar
- Pollan M, Pastor-Barriuso R, Ardanaz E, Arguelles M, Martos C, Galceran J, Sanchez-Perez MJ, Chirlaque MD, Larranaga N, Martinez-Cobo R, et al: Recent changes in breast cancer incidence in Spain, 1980-2004. J Natl Cancer Inst. 2009, 101 (22): 1584-1591. 10.1093/jnci/djp358.View ArticlePubMedPubMed CentralGoogle Scholar
- Marshall JG, Cowell JM, Campbell ES, McNaughton DB: Regional variations in cancer screening rates found in women with diabetes. Nurs Res. 59 (1): 34-41. 10.1097/NNR.0b013e3181c3bd07.
- Reynolds P, Hurley S, Goldberg DE, Anton-Culver H, Bernstein L, Deapen D, Horn-Ross PL, Peel D, Pinder R, Ross RK, et al: Regional variations in breast cancer among California teachers. Epidemiology. 2004, 15 (6): 746-754. 10.1097/01.ede.0000134863.45834.50.View ArticlePubMedGoogle Scholar
- Clarke CA, Purdie DM, Glaser SL: Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors. BMC Cancer. 2006, 6: 170-10.1186/1471-2407-6-170.View ArticlePubMedPubMed CentralGoogle Scholar
- County of Marin HHS: Marin Community Health Survey. 2001Google Scholar
- Kaiser: Kaiser Member Survey. 1999Google Scholar
- Banks E, Beral V, Cameron R, Hogg A, Langley N, Barnes I, Bull D, Elliman J, Harris CL: Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat. 2001, 6 (4): 357-363. 10.1080/13595220152601837.View ArticlePubMedGoogle Scholar
- California Cancer Registry website. California Cancer Registry. 2008, [http://www.ccrcal.org/]
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/10/228/prepub